Adelaide's Royal Adelaide Hospital Cancer Centre and private oncology practices manage prostate cancer patients from across South Australia requiring Abiraterone therapy. For Adelaide patients not meeting PBS eligibility criteria or treating privately, Abiranamo 250mg provides the same life-extending clinical outcomes as brand Zytiga at dramatically reduced cost — enabling sustained therapy that might otherwise be financially unsustainable.
South Australia's significant rural and regional population — including farming communities in the Barossa Valley, Eyre Peninsula, and Murray Mallee regions — often seek specialist oncology care in Adelaide. For these patients managing mCRPC while maintaining working farm operations and rural lifestyles, affordable medication is particularly important since travel costs to Adelaide for specialist care already create significant financial burden.
Visit medshopy.com or WhatsApp +91 82650 41513 for Adelaide supply.
South Australia's significant rural and regional population — including farming communities in the Barossa Valley, Eyre Peninsula, and Murray Mallee regions — often seek specialist oncology care in Adelaide. For these patients managing mCRPC while maintaining working farm operations and rural lifestyles, affordable medication is particularly important since travel costs to Adelaide for specialist care already create significant financial burden.
Visit medshopy.com or WhatsApp +91 82650 41513 for Adelaide supply.
How does PSA (prostate-specific antigen) monitoring work during Abiranamo treatment?PSA is a protein produced by prostate cells — including cancer cells — and its blood level is used as an indicator of prostate cancer activity. During Abiranamo treatment, PSA levels are typically checked every 4-12 weeks. A falling PSA generally indicates the cancer is responding well to Abiraterone's androgen suppression. However, PSA interpretation in mCRPC requires nuance — some patients experience a PSA "surge" in the first 4-8 weeks of starting treatment that reverses later (called PSA flare), which can be misinterpreted as treatment failure if not anticipated. Rising PSA after initial response may indicate disease progression, but clinical and radiological assessment is needed alongside PSA trends to make treatment change decisions. PSA alone is never used as the sole basis for stopping Abiranamo — Adelaide's oncologists use it as one of several monitoring tools.
